Zobrazeno 1 - 10
of 57
pro vyhledávání: '"May-Lill Garly"'
Autor:
Anthony K. Chan, Jayanthi Alamelu, Chris Barnes, Ampaiwan Chuansumrit, May‐Lill Garly, Rikke Medom Meldgaard, Guy Young
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 7, Pp 1101-1113 (2020)
Abstract Background/Objective We report the first analysis of an extended half‐life recombinant factor IX, nonacog beta pegol (N9‐GP), in previously untreated patients (PUPs) and minimally treated patients with hemophilia B. Methods Paradigm 6 (S
Externí odkaz:
https://doaj.org/article/9d21f64616344e6c8eaa8aafa8249a71
Autor:
Lone Hvitfeldt Poulsen, Bryce A. Kerlin, Giancarlo Castaman, Angelo Claudio Molinari, Marzia Menegatti, Diane Nugent, Sohan Dey, May‐Lill Garly, Manuel Carcao
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 2, Pp n/a-n/a (2022)
Abstract Background Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A‐subunit deficiency (FXIII‐A CD). Recombinant factor XIII‐A2 (rFXIII‐A2) was extensively evaluated in the mentor trials. Objective To asse
Externí odkaz:
https://doaj.org/article/5a6d8df7f0b441e8a7dd4b247b17f799
Autor:
Kristoffer Jarlov Jensen, Mia Søndergaard, Andreas Andersen, Erliyani Sartono, Cesario Martins, May-Lill Garly, Jesper Eugen-Olsen, Henrik Ullum, Maria Yazdanbakhsh, Peter Aaby, Christine Stabell Benn, Christian Erikstrup
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97536 (2014)
After measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of
Externí odkaz:
https://doaj.org/article/a45f6a87a33c4d04bd22efc39e9a5c1c
Autor:
Lone Hvitfeldt, Poulsen, Bryce A, Kerlin, Giancarlo, Castaman, Angelo Claudio, Molinari, Marzia, Menegatti, Diane, Nugent, Sohan, Dey, May-Lill, Garly, Manuel, Carcao
Publikováno v:
Research and practice in thrombosis and haemostasis. 6(2)
Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A-subunit deficiency (FXIII-A CD). Recombinant factor XIII-ATo assess real-world safety and treatment effectiveness of rFXIII-Amentor 6 was a noninterventional, postau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ca013747953076f2c32caa8fbf312a5
https://pubmed.ncbi.nlm.nih.gov/35243202
https://pubmed.ncbi.nlm.nih.gov/35243202
Autor:
Michael Williams, Andrew M. Will, Lotte Jacobsen, Bryce A. Kerlin, Aida Inbal, May-Lill Garly, Susan L. Kearney
Publikováno v:
Journal of Thrombosis and Haemostasis. 15:1601-1606
SummaryBackground Factor XIII deficiency is a rare, severe congenital bleeding disorder. Monthly prophylaxis with recombinant factor XIII (rFXIII) has demonstrated favorable safety and efficacy in patients ≥6 years and may similarly benefit younger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c6e1689196d808b9b3293d622b2225
https://doi.org/10.1111/jth.13748
https://doi.org/10.1111/jth.13748
Autor:
Adam Roth, May-Lill Garly, Amalie Timmermann, Peter Aaby, Ane Bærent Fisker, Frederik Schaltz-Buchholzer, Mike L.T. Berendsen, Christine Stabell Benn
Publikováno v:
Benn, C S, Roth, A, Garly, M L, Fisker, A B, Schaltz-Buchholzer, F, Timmermann, A, Berendsen, M & Aaby, P 2020, ' BCG scarring and improved child survival : a combined analysis of studies of BCG scarring ', Journal of Internal Medicine, vol. 288, no. 6, pp. 614-624 . https://doi.org/10.1111/joim.13084
Bacillus Calmette–Guérin (BCG) vaccine against tuberculosis (TB) is recommended at birth in TB-endemic areas. Currently, BCG vaccination programmes use “BCG vaccination coverage by 12 months of age” as the performance indicator. Previous studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba4ba11ca7df10068b9f03c05708e41
https://pubmed.ncbi.nlm.nih.gov/32301189
https://pubmed.ncbi.nlm.nih.gov/32301189
Autor:
Roshni Kulkarni, Carmen Escuriola Ettingshausen, Rikke Medom Meldgaard, Paula Persson, Rajiv K. Pruthi, May-Lill Garly, Inga Hegemann, Robert Klamroth, Adam Cuker, Mindy L. Simpson
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Background and Objective Nonacog beta pegol (N9‐GP) and recombinant factor IX‐Fc fusion protein (rFIXFc) are extended half‐life rFIX compounds. We report the first single‐dose pharmacokinetic trial of N9‐GP and rFIXFc. Patients/Methods Para
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2953000801cca126514cb3b6a5df67a9
https://doi.org/10.5167/uzh-184576
https://doi.org/10.5167/uzh-184576
Autor:
Bryce A. Kerlin, Katsuyuki Fukutake, Johannes Oldenburg, Manuel Carcao, Aida Inbal, May-Lill Garly, Craig M. Kessler, Anders Rosholm, Giancarlo Castaman, Carmen Altisent, Diane J. Nugent, Riitta Lassila
Publikováno v:
Thrombosis and Haemostasis
Recombinant factor XIII-A2 (rFXIII-A2) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a367797ec2fd317441bde1537d470e94
http://hdl.handle.net/10138/233934
http://hdl.handle.net/10138/233934
Autor:
Christine Stabell Benn, Amabelia Rodrigues, Cesario Martins, Andreas Andersen, Peter Aaby, Hilton Whittle, May-Lill Garly, Henrik Ravn, Ane Bærent Fisker, Mogens H. Claesson
Publikováno v:
Aaby, P, Martins, C L, Garly, M-L, Andersen, A, Fisker, A B, Claesson, M H, Ravn, H, Rodrigues, A, Whittle, H C & Benn, C S 2014, ' Measles vaccination in the presence or absence of maternal measles antibody : impact on child survival ', Clinical Infectious Diseases, vol. 59, no. 4, pp. 484-492 . https://doi.org/10.1093/cid/ciu354
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In 2-dose trials, early measles vaccination at 4–6 months in presence of maternal measles antibody was associated with significantly better survival to age 5 years than vaccination in absence of measles antibody. Confounding factors did not explain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1524d4ed31520304102c36cac09eb2f6
https://doi.org/10.1093/cid/ciu354
https://doi.org/10.1093/cid/ciu354
Autor:
Carlitos Balé, Christine Stabell Benn, Cesario Martins, Hilton Whittle, Peter Aaby, Amabelia Rodrigues, May-Lill Garly
Publikováno v:
Martins, C, Garly, M-L, Bale, C, Rodrigues, A, Benn, C S, Whittle, H & Aaby, P 2013, ' Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age : a serological study within a randomised trial of different measles vaccines ', Vaccine, vol. 31, no. 48, pp. 5766-71 . https://doi.org/10.1016/j.vaccine.2013.08.044
Standard–titre Schwarz (SW) and Edmonston-Zagreb (EZ) measles vaccines (MV) are both used in the routine immunisation programme. Within a trial of different strains of MV, we examined antibody responses in both one-dose and two-dose schedules when
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5427a131aa0e0fb149ba0da56946fea